|
Cambridge UK, October 2009
Isogenica Ltd, developer of innovative molecular evolution technologies, has appointed Dr Kevin Matthews as CEO.
Prior to joining Isogenica Kevin was CEO at Oxonica plc from 2001 - 2009, one of the UK’s leading nanotechnology businesses.
In addition to his role at Isogenica Kevin is also a Non-Executive Director and Chairman of the remuneration committee of Elementis plc, a UK listed international speciality chemicals business.
He is also Chairman of the Nanotechnology KTN, a technology strategy board funded organisation with the mission of improving links between technologists and businesses to accelerate the commercialisation of nanotechnology in the UK.
Having spent the last 15 years taking new technologies to market Kevin is very familiar with the challenges of financing, technology development and protection, and commercialisation of new products both through direct sales and licensing across a broad range of industries including pharmaceutical, biotech, medical device, oil, transport, cosmetics, coatings, and speciality chemicals.
-Ends-
Press enquiries:
Kevin Matthews, Isogenica Ltd
M: +44 1799 533682
E:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Note to Editor
About Isogenica:
Isogenica specialises in providing protein engineering services using its core technology, “CIS display”, to pharmaceutical and biotechnology companies for the discovery, identification and design of new peptide, polypeptide and antibody lead compounds. The technology is adaptable for the display of different proteins and has been licensed for the Centyrin scaffold.
www.isogenica.com
|
